Milestone Pharmaceuticals Inc. (MIST) News
Follow Milestone Pharmaceuticals Inc. (MIST) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Milestone Pharmaceuticals Inc. (MIST) Expands Phase 3 AFib-RVR Trial to Canada
Milestone Pharmaceuticals enrolled the first Canadian participant in its ReVeRA-301 Phase 3 trial of etripamil nasal spray for AFib-RVR, targeting ~150 treated events and using the FDA-approved 70 mg repeat-dose regimen
REGULATION | Sep 24, 2026, 12:03 PM UTC
L
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of EtripamilMONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. NAS
NEWS | Sep 24, 2026, 12:03 PM UTC
L
MIST - Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
MIST - Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
NEWS | Sep 24, 2026, 12:00 PM UTC
L
MIST: Rapid drug launch, strong provider uptake, and AFib trial progress drive growth outlook
FDA approval and rapid launch of a new drug have led to positive provider feedback and growing patient momentum. Electrophysiologists are adopting quickly, and a phase III AFib trial is underway, leveraging prior experie
REGULATION | Sep 15, 2026, 03:28 PM UTC
L
MIST: Rapid drug launch, strong EP adoption, and efficient AFib trial drive growth and financial stability
FDA approval and rapid launch of a new drug have driven positive prescriber and patient feedback, with strong early adoption among electrophysiologists and growing refill rates. The phase III AFib program leverages prior
REGULATION | Sep 15, 2026, 03:10 PM UTC
L
MIST’s CARDAMYST launch gains momentum on adoption and coverage
CARDAMYST’s launch is seeing strong adoption by electrophysiologists and positive payer coverage, with efforts shifting to cardiologist awareness. Revenue per script is expected to rise as coverage expands and free drug
EQUITY | Sep 08, 2026, 06:55 PM UTC
H
Milestone Pharmaceuticals gets NMPA approval for etripamil
Milestone Pharmaceuticals announced NMPA approval of etripamil nasal spray for adult PSVT and a $2.0 million milestone payment.
REGULATION | Sep 03, 2026, 08:42 PM UTC
L
HC Wainwright maintains $8.00/share price target on MIST
HC Wainwright & Co. maintained its $8.00 per share price target for Milestone Pharmaceuticals, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 04:05 PM UTC
L
Milestone Pharmaceuticals NMPA approval triggers $2 million milestone payment
Milestone Pharmaceuticals (NASDAQ:MIST) says NMPA approval triggers a $2 million milestone payment to the company.
EQUITY | Sep 03, 2026, 02:47 PM UTC
M
Milestone Pharmaceuticals gets NMPA approval for Etripamil nasal spray in China
Milestone Pharmaceuticals said China’s NMPA approved its etripamil nasal spray for PSVT, the first Etripamil regulatory approval outside the United States.
GEOPOLITICS | Sep 03, 2026, 01:37 PM UTC
L
Milestone Pharmaceuticals management to present at upcoming investor conferences
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) said management will present at and participate in upcoming investor conferences, according to a company announcement.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
MIST - Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MIST - Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
Milestone Pharmaceuticals presents PSVT quality-of-life data at ESC 2026
Milestone Pharmaceuticals said it presented data at ESC Congress 2026 on PSVT’s impact on patients’ daily lives and quality of life between episodes.
GEOPOLITICS | Aug 27, 2026, 12:07 PM UTC
H
MIST - Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSV
MIST - Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
GEOPOLITICS | Aug 27, 2026, 12:00 PM UTC
M
Milestone Pharmaceuticals starts pivotal Phase 3 trial of etripamil nasal spray
Milestone Pharmaceuticals initiated a pivotal Phase 3 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).
CENTRAL_BANK | Aug 21, 2026, 12:00 PM UTC
M
Cantor Fitzgerald initiates MIST at Overweight, $3.00 target
Cantor Fitzgerald initiates MIST with an Overweight rating and a $3.00 price target.
EQUITY | Aug 20, 2026, 11:56 AM UTC
L
MIST Announces Q2 2026 Financial Results
Milestone Pharmaceuticals announces second quarter 2026 financial results and provides corporate update
EARNINGS | Aug 12, 2026, 11:08 AM UTC
L
MIST - Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
MIST - Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
EARNINGS | Aug 04, 2026, 08:01 PM UTC
L
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals
EQUITY | Jul 03, 2026, 01:30 AM UTC